Bristol Myers Squibb (BMY) Stock Analysis: Advancing the Pipeline While Managing Patent Headwinds
Key Takeaways
-
Q4 2025 revenue reached $12.5 billion, exceeding expectations, with growth portfolio sales up 16% year-over-year.
-
Full-year 2025 revenue totaled $48.2 billion, supported by Eliquis, Opdivo, and newer products including Breyanzi and Camzyos.
-
2026 guidance calls for revenue of $46.0–$47.5 billion and non-GAAP EPS of $6.05–$6.35, both ahead of consensus.
-
Analysts raised price targets following earnings, though the overall consensus rating remains Hold, with an average target near $59–$60.
-
Strategic initiatives, including an AI-driven oncology collaboration with Microsoft, strengthen the long-term pipeline outlook.
-
Shares have rebounded recently as investors weigh growth momentum against legacy drug erosion.
Market Snapshot: Recovery on Strong Results
Bristol Myers Squibb (BMY) shares have rebounded from recent lows, supported by solid quarterly results and better-than-expected 2026 guidance. While patent expirations and generic competition continue to pressure legacy brands such as Revlimid and Pomalyst, strength in the company’s growth portfolio has improved investor sentiment.
The stock’s recovery reflects renewed confidence that expanding contributions from newer therapies can help offset anticipated revenue erosion later in the decade.
Earnings Review: Growth Portfolio Gains Traction
Bristol Myers reported Q4 2025 revenue of $12.5 billion, up 1.3% year-over-year and roughly 2% above consensus expectations. Non-GAAP EPS came in at $1.26, surpassing forecasts of $1.15.
For the full year, revenue reached $48.2 billion.
Growth Portfolio Highlights
Growth portfolio revenue increased 16% year-over-year to $7.4 billion in Q4, led by:
-
Eliquis, benefiting from pricing adjustments and steady demand
-
Opdivo and Yervoy in immuno-oncology
-
Breyanzi, with sales up 82%
-
Camzyos, which posted 77% growth
These gains helped offset ongoing declines in legacy therapies facing generic competition.
Management emphasized that the growth portfolio now represents a rising share of total revenue, positioning the company for a gradual transition away from mature products.
2026 Guidance: Above Expectations
Bristol Myers projects 2026 revenue of $46.0–$47.5 billion and non-GAAP EPS of $6.05–$6.35. Both ranges exceed prior Street expectations of roughly $44.2 billion in revenue and $6.04 in EPS.
Key assumptions include:
-
Eliquis growth of 10–15% globally, despite Medicare price negotiations under the Inflation Reduction Act (IRA).
-
Legacy portfolio declines of 12–16%, reflecting continued generic pressure.
Management expects increased volume from improved affordability to help offset mandated pricing reductions for Eliquis beginning in 2026.
Analyst Reaction: Cautious Optimism
Analyst responses were generally constructive, though tempered by long-term patent risks.
Recent price target revisions include:
-
Citi: $64
-
Bank of America: $68
-
Morgan Stanley: $40 (raised from $37)
-
Wells Fargo: reiterated Outperform at $60
The consensus rating remains Hold, with an average price target around $59–$60. Shares recently traded near that range after touching 52-week highs around $63.
Investors appear encouraged by near-term growth execution but mindful of upcoming exclusivity losses later in the decade, particularly for Eliquis and Opdivo.
Strategic Initiatives Strengthen Oncology Focus
Bristol Myers continues investing in pipeline expansion and innovation.
In January 2026, the company announced a collaboration with Microsoft to develop AI-driven tools for early lung cancer detection, reinforcing its oncology capabilities. Additional awareness campaigns, including partnerships promoting Breyanzi, highlight commercialization efforts in hematologic cancers.
Management describes its current portfolio as the “richest product pipeline in a decade,” with up to 12 late-stage readouts expected across eight assets spanning oncology, cardiology, and cell therapy.
Recent acquisitions and research expansions, including radiopharmaceutical and immunotherapy initiatives, further strengthen long-term positioning.
Capital Allocation and Income Appeal
Bristol Myers increased its quarterly dividend to $0.63 per share, resulting in a dividend yield of approximately 4%. The payout reinforces the stock’s appeal among income-oriented investors while pipeline investments continue.
R&D spending remains substantial at roughly $10 billion annually, reflecting a strategy focused on sustaining innovation despite near-term earnings pressure.
2026 Outlook: Key Variables to Watch
1. Growth Portfolio Execution
The growth portfolio now approaches 60% of total revenue. Sustained uptake of Breyanzi, Camzyos, and Opdivo expansions will be critical in offsetting legacy declines.
2. IRA Pricing Impact
The Inflation Reduction Act introduces Medicare pricing negotiations for key drugs. While Eliquis volumes may benefit from lower prices, expanded government negotiations could introduce additional revenue headwinds in 2028 and beyond.
3. Late-Stage Pipeline Readouts
Multiple Phase III trials and regulatory milestones are expected in 2026. Positive data could materially shift long-term revenue projections.
4. Competitive and Patent Risks
Competition in immuno-oncology and cardiovascular markets remains intense. Patent cliffs later in the decade represent a structural risk that management must counter through pipeline execution and business development.
Bottom Line
Bristol Myers Squibb (BMY) is navigating a pivotal transition period. Strong performance from its growth portfolio and above-consensus 2026 guidance have restored investor confidence in the near term. However, legacy drug erosion and regulatory pricing reforms remain meaningful long-term challenges.
The company’s ability to deliver on its deep late-stage pipeline and sustain growth beyond key patent expirations will determine whether the recent rebound marks the beginning of a sustained re-rating or a temporary recovery within a longer transition cycle.
Tickeron AI Perspective
Disclaimers and Limitations
BMY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BMY turned positive on June 26, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 15, 2026. You may want to consider a long position or call options on BMY as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
BMY moved above its 50-day moving average on July 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on July 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BMY broke above its upper Bollinger Band on June 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMY entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.974) is normal, around the industry mean (19.583). P/E Ratio (16.448) is within average values for comparable stocks, (27.548). Projected Growth (PEG Ratio) (1.526) is also within normal values, averaging (3.872). Dividend Yield (0.043) settles around the average of (0.031) among similar stocks. P/S Ratio (2.472) is also within normal values, averaging (4.121).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor
Advertisement